|Bid||4.2300 x N/A|
|Ask||4.2400 x N/A|
|Day's Range||4.1700 - 4.2600|
|52 Week Range||3.9800 - 9.4000|
|Beta (5Y Monthly)||1.31|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Aptose Biosciences Inc (NASDAQ: APTO) highlighted data from its luxeptinib currently in two Phase 1 a/b trials - one in relapsed or refractory acute myeloid leukemia (AML) and another in relapsed or refractory B cell malignancies. In Relapsed or Refractory AML or High-Risk MDS trial, APTO-253 has been well-tolerated in the patients treated at 20, 40, 66, 100, and 150 mg/m2 over multiple cycles supporting continued dose escalation. APTO-253 monomer rapidly transformed to and co-existed with the F
Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.
The big shareholder groups in Aptose Biosciences Inc. ( TSE:APS ) have power over the company. Institutions often own...